SCHEMBL3925919

SCHEMBL3925919

CSCCC1NC2(CCN(C(=S)NCc3ccc(Cl)cc3)CC2)N(Cc2ccccc2C#N)C1=O

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.37
MEN1 O00255 6/20 0.37
POLB P06746 4/20 0.37
MAPT P10636 4/20 0.35
HTT P42858 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ACHE P22303 1/20 0.34
CHRM4 P08173 1/20 0.33
GAA P10253 2/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ARG1 P05089 1/20 0.32
ARG2 P78540 1/20 0.32
CACNA1G O43497 1/20 0.32
CHRM1 P11229 1/20 0.32
METAP2 P50579 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925417 0.86 MEN1 (0.41) KMT2AMEN1POLBMAPTHTT
SCHEMBL4035555 0.86 ACHE (0.32) MAPTACHECHRM4ALDH1A1CACNA1G
SCHEMBL3920554 0.86 KDM4E (0.36) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL4038594 0.85 P2RX7 (0.33) KMT2AMAPTSMN1; SMN2CHRM4GAA
SCHEMBL3925602 0.84 GAA (0.36) KMT2ASMN1; SMN2CHRM4GAAALDH1A1
SCHEMBL3926877 0.84 HRH3 (0.39) KMT2AMEN1HTTSMN1; SMN2CHRM4
SCHEMBL3927003 0.83 DRD4 (0.39) KMT2AMEN1GAAALDH1A1LMNA
SCHEMBL3916351 0.82 GAA (0.34) KMT2AMAPTSMN1; SMN2CHRM4GAA
SCHEMBL3916341 0.82 POLB (0.40) KMT2AMEN1POLBSMN1; SMN2GAA
SCHEMBL3917520 0.81 KDM4E (0.40) KMT2AMEN1MAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 KMT2A 4051/4885MEN1 1493/4885POLB 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.